Come join our group! Please share with those interested.

careers.dana-farber.org/job/scientist-…

In the weeks since our work on RAS inhibition was published, we have received many emails and calls from PDAC patients. To educate and disseminate info, I've posted a discussion on our website targeted to lay audience, addressing common patient questions. olivelab.org/ras-inhibitor-…

Just published with the #AACR24 presentation in Attacking #KRAS Beyond G12C:
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers, by Jingjing Jiang, Zhengping Wang, Mallika Singh et al.
bit.ly/3vNIQ1A
#RevolutionMedicines

Thanks to Haeseong Park, MD, MPH, of Dana-Farber for stopping by for an interview on her AACR presentation on a phase 1 trial of epacadostat plus preoperative chemoradiation in locally advanced rectal cancer #AACR2024

Quite simply, this was the strongest performing single agent we have encountered. In the highly chemoresistant KPC model, RMC-7977 produced the longest extension of survival ever reported. Almost all tumors regressed, some for extended durations (>6 months). This is new for us.

Out in nature concurrent with #AACR24
Two papers on biochemistry and preclinical characterization of Revolution Medicines’ RAS(ON) multiRAS inhibitor, with a focus on #PancreaticCancer
KenOliveLab Ben Stanger Der Lab at UNC
nature.com/articles/s4158…
nature.com/articles/s4158…

FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. fda.gov/drugs/resource…

#OCENewsBurst

There were over half a million reported new cases of #PancreaticCancer worldwide, and it is responsible for almost 5% of all cancer deaths worldwide. With the exception of unusual outliers, the SIR in both males & females in highest in Europe & Northern America. OncoAlert

👏We want to congratulate the new members of the ASCO #TECAG '24-'25.
This year, we had an overwhelming number of highly qualified applicants. Unfortunately, there were not enough spots for everyone.
There are many other ways to be involved w/ASCO that we HIGHLY recommend:
🧵

Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

It was a privilege to present the exploratory analyses of #HPV circulating DNA Naveris, Inc. in our Dana-Farber trial studying pembrolizumab in anal cancer at #EUROGIN2024 !

Excitingly, the results were published in Journal for ImmunoTherapy of Cancer: jitc.bmj.com/content/12/1/e…


James Cleary EUROGIN Conference

ASCO AACR #Vail #Cancer #Research Workshop application is open, deadline March 27! vailworkshop.org

Apply for the @ASCO@AACR Methods in Clinical Research Workshop. A great experience for HemOnc Fellows and junior faculty! Applications due soon!

My research has been supported by the selfless #TeamPerry #PMC2024 riders in honor of Perry Levy- a young man who had a GI cancer. As their Fellow, I had the honor of sharing our work which could not be done without their efforts - surpassing $10 million!

profile.pmc.org/TT0046

Congratulations to Harsh, James, and team on a very well done description of the unique entity - #HER2 (ERBB2) amplified CRC! Exciting translational work happening at Dana-Farber Dana-Farber's Young-Onset Colorectal Cancer Center Dana-FarberNews!

#crcsm Clinical Cancer Research OncoAlert OncoDaily

We find encouraging signs of activity of trastuzumab deruxtecan in #KRAS mutated #CRCs with high level HER2 amplification.

Grateful to patients & co-authors who made this possible.

Steven Corsello Kimmie Ng, MD, MPH A.n.n. Foundation Medicine Brandon Huffman, MD OncoAlert Colorectal Cancer Alliance @danafarber